2022
Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations
Jin S, Jiang N, Huo Y, Duan X, Fang Y, Zhao C, Li H, Yang M, Huang Z, Yang P, Zhang H, Zhan F, Wang Y, Wang Y, Wu C, Wang Q, Hsieh E, Li M, Tian X, Zhao Y, Zeng X. Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations. Annals Of The Rheumatic Diseases 2022, 81: 1052-1054. PMID: 35168947, DOI: 10.1136/annrheumdis-2021-221841.Peer-Reviewed Original Research
2021
Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment
Hanberg JS, Hsieh E, Akgün KM, Weinstein E, Fraenkel L, Justice AC, Team T. Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment. Arthritis & Rheumatology 2021, 73: 2189-2199. PMID: 34042306, DOI: 10.1002/art.41802.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntirheumatic AgentsArthritis, RheumatoidComorbidityFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedPrevalenceConceptsDisease-modifying antirheumatic drugsIncident rheumatoid arthritisDiagnosis of RARA patientsRheumatoid arthritisRheumatoid factorUninfected individualsRheumatology/European AllianceHigh titersVeterans Aging Cohort StudyRA-specific autoantibodiesRheumatology 2010 criteriaTenth Revision codesAging Cohort StudyIncidence rate ratiosHigh autoantibody titersICD-10 codesDMARD useUninfected veteransAntirheumatic drugsAutoantibody titersCohort studyImmunosuppressed populationHIV infectionMedical charts
2020
Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow‐ups and predictors of achieving treatment target
Xiang Y, Wang Q, Li H, Duan X, Fang Y, Yang P, Li Q, Wu R, Huo Y, Shi X, Wu Z, Wang Y, Jiang N, Hsieh E, Li M, Tian X, Zeng X, co‐authors C. Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow‐ups and predictors of achieving treatment target. International Journal Of Rheumatic Diseases 2020, 23: 1719-1727. PMID: 33034424, DOI: 10.1111/1756-185x.13996.Peer-Reviewed Original ResearchConceptsBiologic disease-modifying anti-rheumatic drugsDisease activityTreatment responseChinese RegistryRheumatoid arthritisDisease-modifying anti-rheumatic drugsBaseline Disease Activity ScoreConventional DMARD therapyLower baseline DAS28Baseline disease activityDisease Activity ScoreAnti-rheumatic drugsBaseline DAS28DMARD therapyLDA ratesPrednisolone usageSynthetic DMARDsEarly RADisease durationActivity scoreTreatment strategiesTreatment targetsYounger agePatientsBaseline